| |
 |
Henry B. Abajian Patents |
|
Inventor: Abajian; Henry B.
Address: Hillsdale, NJ
No. of patents: 5
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| 6767897 |
Therapeutic uses of tri-, tetra-, penta-, and polypeptides |
July 27, 2004 |
| Novel uses of certain peptides to treat patients suffering from neurological or psychiatric disorders are disclosed. The peptides include the tripeptide hormone MIF and compounds made by modifications of MIF, such as modification of amino terminus residues, carboxyl terminus residues |
| 6093797 |
Tri-, Tetra-, Penta-, and polypeptides and their therapeutic use as an antidepressant agent |
July 25, 2000 |
| The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including additi |
| 5990172 |
Peptidomimetics for the treatment of HIV infection |
November 23, 1999 |
| This invention provides peptidomimetics which bind to T4 or CD4 cell receptors and are useful in inhibiting viral infectivity by viruses which bind to T4 cell receptors. More specifically, peptidomimetics of this invention can alleviate symptoms of AIDS by inhibiting binding of HIV, the |
| 5767083 |
Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent |
June 16, 1998 |
| The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including additi |
| 5589460 |
Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent |
December 31, 1996 |
| The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including additi |
|
|
|
